Skip to main content

Advertisement

SpringerLink
Log in

Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study

  • Clinical Trial
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To evaluate the potential role of tegaserod in the management of functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) in patients with chronic constipation and to determine the possible efficacy of tegaserod on solid-phase gastric emptying and gastric hypersensitivity.

Method

This was an exploratory open-label trial of tegaserod therapy for dyspepsia and reflux symptoms in patients with chronic constipation. The study cohort consisted of 90 patients randomized to three treatment groups for a study period of 4 weeks (tegaserod 6 mg, twice daily; esomeprazole 40 mg, once daily; tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily). Twenty healthy volunteers provided control values. Clinical symptoms were evaluated by one of the investigators using a Gastrointestinal Symptom Rating Scale (GSRS). Solid-phase gastric emptying and colonic transit were measured by the radiopaque barium marker method, and the water load test (WLT) was used to evaluate gastric sensation and the function of proximal stomach. The proportions of patients with complete relief of epigastric pain /discomfort, epigastric fullness, early satiety and heartburn in the tegaserod group and the tegaserod plus esomeprazole group were compared with the esomeprazole group, respectively.

Results

The mean global gastrointestinal (GI) scores of all three treatment groups reported using the GSRS showed the same trend, with decreasing scores over the 4-week study period indicating a reported decreasing severity of symptoms that was significantly different from baseline values. Patients in the tegaserod plus esomeprazole group reported the lowest global GI scores after 4 weeks, as expected. Solid-phase gastric emptying (GER) and colonic transit (CTT) increased significantly in the tegaserod 6 mg twice daily group compared with baseline. These parameters did not change in the esomeprazole group at week 4 compared with baseline. In terms of gastric sensation, in the tegaserod group, the proportions of patients with hypersensitivity of the first perception threshold did not change at week 2 or week 4 compared with baseline; however, in this group and in the tegaserod plus esomeprazole group, the proportions of patients with hypersensitivity of discomfort threshold decreased significantly at week 4 compared with baseline. In the esomeprazole group, there were no changes in the proportions of patients with hypersensitivity of the first perception threshold and discomfort threshold at week 2 or 4 compared with baseline. No severe adverse events were recorded, and the medications were in general well-tolerated.

Conclusion

Tegaserod is effective and safe at improving dyspepsia and reflux symptoms in patients with chronic constipation, and tegaserod plus esomeprazole is superior to esomeprazole alone in the resolution of epigastric pain/discomfort and heartburn.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wong WM, Lai KC, Lam KF, Hui WM, Hu WH, Lam CL, Xia HH, Huang JQ, Chan CK, Lam SK, Wong BC (2003) Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 18(6):595–604

    Article  PubMed  CAS  Google Scholar 

  2. Wong WM, Lai KC, Lam KF, Hui WM, Huang JQ, Xia HH, Hu WH, Lam CL, Chan CK, Lam SK, Wong BC (2004) Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study. Aliment Pharmacol Ther 20(7):803–812

    Article  PubMed  CAS  Google Scholar 

  3. Talley NJ, Lam SK, Goh KL, Fock KM (1998) Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia. J Gastroenterol Hepatol 13(4):335–353

    PubMed  CAS  Google Scholar 

  4. Hu WHC, Hui WM, Lam SK (1997) Anxiety and depression are co-factors determining health care utilization in patient with dyspepsia: a Hong Kong population based study. Gastroenterology 112:A153

    Google Scholar 

  5. Ho KY, Kang JY, Seow A (1998) Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 93(10):1816–1822

    Article  PubMed  CAS  Google Scholar 

  6. Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ (2004) A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmacol Ther 19(11):1217–1224

    Article  PubMed  CAS  Google Scholar 

  7. Kwan AC, Hu WH, Chan YK, Yeung YW, Lai TS, Yuen H (2002) Prevalence of irritable bowel syndrome in Hong Kong. J Gastroenterol Hepatol 17(11):1180–1186

    Article  PubMed  Google Scholar 

  8. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE (2000) Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus, 2nd edn. Degnon Associates, McLean

    Google Scholar 

  9. Caballero-Plasencia AM, Sofos-Kontoyannis S, Valenzuela-Barranco M, Martin-Ruiz JL, Casado-Caballero FJ, Lopez-Manas JG (1999) Irritable bowel syndrome in patients with dyspepsia: a community-based study in southern Europe. Eur J Gastroenterol Hepatol 11(5):517–522

    Article  PubMed  CAS  Google Scholar 

  10. Agreus L, Svardsudd K, Nyren O, Tibblin G (1995) Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109(3):671–680

    Article  PubMed  CAS  Google Scholar 

  11. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD (2003) Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 98(11):2454–2459

    Article  PubMed  Google Scholar 

  12. Talley NJ, Piper DW (1985) The association between non-ulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol 20(7):896–900

    PubMed  CAS  Google Scholar 

  13. Guillemot F, Ducrotte P, Bueno L (2005) Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol 29(3):243–246

    Article  PubMed  Google Scholar 

  14. Mertz H, Naliboff B, Mayer EA (1999) Symptoms and physiology in severe chronic constipation. Am J Gastroenterol 94(1):131–138

    Article  PubMed  CAS  Google Scholar 

  15. Agreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G (2001) Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 96(10):2905–2914

    PubMed  CAS  Google Scholar 

  16. Cremonini F, Talley NJ (2004) The overlap between functional dyspepsia and irritable bowel syndrome – a tale of one or two disorders? Aliment Pharmacol Ther 20[Suppl 7]:40–49

    Article  PubMed  Google Scholar 

  17. Tack J, Vos R, Janssens J, Salter J, Jauffret S, Vandeplassche G (2003) Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 18(10):1031–1037

    Article  PubMed  CAS  Google Scholar 

  18. Degen L, Petrig C, Studer D, Schroller S, Beglinger C (2005) Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 17(6):821–826

    Article  PubMed  CAS  Google Scholar 

  19. Svedlund J, Sjödin I, Dotevall G (1988) GSRS – A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33(2):129–134

    Article  PubMed  CAS  Google Scholar 

  20. Revicki DA, Wood M, Wiklund I, Crawley J (1998) Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 7(1):75–83

    Article  PubMed  CAS  Google Scholar 

  21. Lassen AT, Hallas J, Schaffalitzky de Muckadell OB (2004) Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial. Gut 53(12):1758–1763

    Article  PubMed  CAS  Google Scholar 

  22. Kikuchi K, Kusano M, Kawamura O, Mori M, Sekiguchi T (2000) Measurement and evaluation of gastric emptying using radiopaque barium markers. Dig Dis Sci 45(2):242–247

    Article  PubMed  CAS  Google Scholar 

  23. Tosetti C, Salvioli B, Stanghellini V, Cogliandro L, Cogliandro R, Marra MG, De Giorgio R, Mazzotta E, Zamboni P, Corinaldesi R (1999) Reproducibility of a water load test in healthy subjects and symptom profile compared to patients with functional dyspepsia. Gastroenterology 116:A336

    Google Scholar 

  24. Li QX, Zhu LR, Hou XH (2004) The clinical study of water loading in gastric sensation thresholds testing. Chin J Intern Med 43(6):436–438

    Google Scholar 

  25. Boeckxstaens GE, Hirsch DP, Berkhout B, Tytgat GN (1999) Is a drink test a valuable tool to study proximal study function? Gastroenterology 116:A960

    Google Scholar 

  26. Anjiki H, Sanaka M, Kuyama Y (2005) Dual effects of rabeprazole on solid-phase gastric emptying assessed by the 13C-octanoate breath test. Digestion 72(2–3):189–194

    Article  PubMed  CAS  Google Scholar 

  27. Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, Maurer AH, Fisher RS (1998) Effect of gastric acid suppressants on human gastric motility. Gut 42(2):243–250

    Article  PubMed  CAS  Google Scholar 

  28. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR (2000) Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 47(4):473–480

    Article  PubMed  CAS  Google Scholar 

  29. McColl KE (2000) No H. pylori: less dyspepsia? Gut 47(4):461–462

    Article  PubMed  CAS  Google Scholar 

  30. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ (2004) Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 116(11):740–748

    Article  PubMed  CAS  Google Scholar 

  31. Farup PG, Hovde O, Torp R, Wetterhus S (1999) Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J Gastroenterol 34(6):575–579

    Article  PubMed  CAS  Google Scholar 

  32. Rodriguez-Stanley S, Wolff M, Proskin HM, Bottoli I, Kralstein J, Miner PB (2005) An exploratory open label trial of tegaserod in non-erosive GERD patients with incomplete response to PPIs. Am J Gastroenterol 100:S38

    Article  Google Scholar 

  33. Rodriguez-Stanley S, Zubaidi S, Proskin HM, Kralstein JR, Shetzline MA, Miner PB Jr (2006) Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastrornterol Hepatol 4(4):442–450

    Article  CAS  Google Scholar 

  34. Tack J, Vos R, Bisschops R, Tougas G, Janssens J, Phillips T (2005) Effect of tegaserod, a 5-HT4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastroenterology 128:A94

    Article  Google Scholar 

  35. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ (2000) The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14(11):1503–1509

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study complies with the current laws of P.R. China.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Qilu Hospital of Shandong University, Wenhua xi Road 107, Jinan, Shandong Province, 250012, People’s Republic of China

    Juan Zeng, Xiu-Li Zuo, Yan-Qing Li & Guo-Ping Lv

  2. Department of Gastroenterology, Central Hospital of Taian, Taian, 271000, People’s Republic of China

    Wei Wei

Authors
  1. Juan Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiu-Li Zuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan-Qing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guo-Ping Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan-Qing Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zeng, J., Zuo, XL., Li, YQ. et al. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study. Eur J Clin Pharmacol 63, 529–536 (2007). https://doi.org/10.1007/s00228-007-0287-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0287-3

Keywords

Search

Navigation